U.S. Markets open in 3 hrs 48 mins

Is Dynavax Technologies Corporation (NASDAQ:DVAX) Worth US$10.80 Based On Intrinsic Value?

Brandon Murphy

How far off is Dynavax Technologies Corporation ( NASDAQ:DVAX ) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to today’s value. I will use the discounted cash flows (DCF) model. It may sound complicated, but actually it is quite simple! If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model . If you are reading this and its not January 2019 then I highly recommend you check out the latest calculation for Dynavax Technologies by following the link below.

Check out our latest analysis for Dynavax Technologies

Want to help shape the future of investing tools and platforms? Take the survey and be part of one of the most advanced studies of stock market investors to date.

What’s the value?

I’m using the 2-stage growth model, which simply means we take in account two stages of company’s growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have perpetual stable growth rate. In the first stage we need to estimate the cash flows to the business over the next five years. For this I used the consensus of the analysts covering the stock, as you can see below. I then discount this to its value today and sum up the total to get the present value of these cash flows.

5-year cash flow estimate

2019 2020 2021 2022 2023
Levered FCF ($, Millions) $-98.00 $-57.00 $-20.00 $57.00 $114.00
Source Analyst x2 Analyst x2 Analyst x1 Analyst x1 Analyst x1
Present Value Discounted @ 13.73% $-86.17 $-44.07 $-13.60 $34.07 $59.92

Present Value of 5-year Cash Flow (PVCF) = -US$49.8m

We now need to calculate the Terminal Value, which accounts for all the future cash flows after the five years. The Gordon Growth formula is used to calculate Terminal Value at an annual growth rate equal to the 10-year government bond rate of 2.7%. We discount this to today’s value at a cost of equity of 13.7%.

Terminal Value (TV) = FCF 2023 × (1 + g) ÷ (r – g) = US$114m × (1 + 2.7%) ÷ (13.7% – 2.7%) = US$1.1b

Present Value of Terminal Value (PVTV) = TV / (1 + r) 5 = US$1.1b ÷ ( 1 + 13.7%) 5 = US$560m

The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is US$510m. The last step is to then divide the equity value by the number of shares outstanding. If the stock is an depositary receipt (represents a specified number of shares in a foreign corporation) then we use the equivalent number. This results in an intrinsic value of $8.13 . Compared to the current share price of $10.8, the stock is quite expensive and not available at a discount at this time.

NasdaqCM:DVAX Intrinsic Value Export January 15th 19

The assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don’t have to agree with my inputs, I recommend redoing the calculations yourself and playing with them. Because we are looking at Dynavax Technologies as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighed average cost of capital, WACC) which accounts for debt. In this calculation I’ve used 13.7%, which is based on a levered beta of 1.513. This is derived from the Bottom-Up Beta method based on comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn’t be the only metric you look at when researching a company. What is the reason for the share price to differ from the intrinsic value? For DVAX, I’ve put together three essential aspects you should look at:

  1. Financial Health : Does DVAX have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Future Earnings : How does DVAX’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart .
  3. Other High Quality Alternatives : Are there other high quality stocks you could be holding instead of DVAX? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St does a DCF calculation for every US stock every 6 hours, so if you want to find the intrinsic value of any other stock just search here .

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com .